期刊
CHINESE JOURNAL OF CANCER
卷 32, 期 5, 页码 270-274出版社
SUN YAT SEN UNIV MED SCI WHO
DOI: 10.5732/cjc.013.10005
关键词
Mutation; mTOR; rapalogs; cancer
类别
资金
- Georgia Cancer Coalition Distinguished Cancer Scholar award
- NIH [R01 CA118450, R01 CA160522, P01 CA116676]
Rapamycin and its derivatives (rapalogs), a group of allosteric inhibitors of mammalian target of rapamycin (mTOR), have been actively tested in a variety of cancer clinical trials, and some have been approved by the Food and Drug Administration for the treatment of certain types of cancers. However, the single agent activity of these compounds in many tumor types remains modest. The mTOR axis is regulated by multiple upstream signaling pathways. Because the genes (e.g., PIK3CA, KRAS, PTEN, and LKB1) that encode key components in these signaling pathways are frequently mutated in human cancers, a subset of cancer types may be addicted to a given mutation, leading to hyperactivation of the mTOR axis. Thus, efforts have been made to demonstrate the potential impact of genetic alterations on rapalog-based or mTOR-targeted cancer therapy. This review will primarily summarize research advances in this direction.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据